By analyzing both gene expression profiles as well as response to neoadjuvant chemotherapy we could firstly, show that SFRP1 expression correlates with the triple negative breast cancer subtype and secondly, demonstrate association between expression of SFRP1 and positive response to neoadjuvant chemotherapy, i.e. achievement of a pathologic complete response (Figure 1A, Tables 1, 2).We next sought to analyze the expression of SFRP1 in breast cancer tissue specimen. This evidence concerns the gene SFRP1 and triple-negative breast carcinoma.